Endotoxin Activity Assay for the Detection of Whole Blood Endotoxemia in Critically Ill Patients

Author(s):  
Riccardo Pinciroli ◽  
Simone Checchi ◽  
Maurizio Bottiroli ◽  
Gianpaola Monti ◽  
Giampaolo Casella ◽  
...  
Critical Care ◽  
2014 ◽  
Vol 18 (Suppl 1) ◽  
pp. P408
Author(s):  
SL Cutuli ◽  
G De Pascale ◽  
V Alicino ◽  
S Cicconi ◽  
V Di Gravio ◽  
...  

2005 ◽  
Vol 33 ◽  
pp. A163
Author(s):  
Kazuaki Atagi ◽  
Natsuko Tokuhira ◽  
Atsushi Ujiro ◽  
Hideki Shimaoka

2021 ◽  
Vol 8 ◽  
Author(s):  
Chen-Tse Lee ◽  
Chih-Hsien Wang ◽  
Wing-Sum Chan ◽  
Yun-Yi Tsai ◽  
Tzu-Jung Wei ◽  
...  

Background: Extracorporeal membrane oxygenation (ECMO) life support has become an integral part of intensive care. The endotoxin activity assay (EAA) is a useful test to measure endotoxemia severity in whole blood. To date, no information is available regarding the EAA levels and their effect on clinical outcomes in critically ill patients with ECMO support.Methods: This prospective observational pilot study enrolled adult critically ill patients with ECMO support from August 2019 to December 2020. The EAA levels were measured within 24 h (T1), and at 25–48 (T2), 49–72 (T3), and 73–96 h (T4) after ECMO initiation. This study primarily aimed to investigate the incidence of high EAA levels (≥0.6) at each time point. Subsequent exploratory analyses were conducted to compare the EAA levels of venoarterial ECMO (VA-ECMO) patients between 30-day survivors and non-survivors. Post-hoc analysis was performed to compare the clinical outcomes of VA-ECMO patients with elevated EAA levels at T3 (vs. T1) and those without elevated EAA levels.Results: A total of 39 VA-ECMO patients and 15 venovenous ECMO (VV-ECMO) patients were enrolled. At T1, the incidence of high EAA level (≥0.6) was 42% in VV-ECMO patients and 9% in VA-ECMO patients (P = 0.02). At T2, the incidence of high EAA level was 40% in VV-ECMO patients and 5% in VA-ECMO patients (P = 0.005). In VA-ECMO patients, EAA levels at T3 were significantly higher in 30-day non-survivors than in survivors (median [interquartile range]: 0.49 [0.37–0.93] vs. 0.31 [0.19–0.51], median difference 0.16 [95% confidence interval [CI], 0.02–0.31]; P = 0.024). Moreover, VA-ECMO patients with elevated EAA levels at T3 (vs. T1) had lower 30-day survival than patients without elevated EAA levels (39 vs. 83%, P = 0.026) and fewer ECMO free days by day 30 (median: 3 vs. 23 days, median difference 12 days [95% CI, 0–22]; P = 0.028).Conclusions: A certain proportion of patients experienced high EAA levels (≥0.6) after VV-ECMO or VA-ECMO initiation. VA-ECMO patients with an elevated EAA level at 49–72 h were associated with poor clinical outcomes.


2013 ◽  
Vol 21 (2) ◽  
pp. 120-127 ◽  
Author(s):  
Mari Sato ◽  
Ryusei Matsuyama ◽  
Toshiaki Kadokura ◽  
Ryutaro Mori ◽  
Takafumi Kumamoto ◽  
...  

Blood ◽  
1997 ◽  
Vol 89 (5) ◽  
pp. 1612-1620 ◽  
Author(s):  
Wolfgang Ertel ◽  
Marius Keel ◽  
Regula Neidhardt ◽  
Ursula Steckholzer ◽  
Jean-Pierre Kremer ◽  
...  

Abstract Interleukin-12 (IL-12) and interferon-γ (IFN-γ) exert protective effects during experimental endotoxemia through upregulation of cellular immunity and phagocytic functions. They are part of a positive regulatory feedback loop that enhances the production of the other. Because critically ill patients show a marked suppression of T-cell and macrophage functions with a high susceptibility to infection, potential defects in the immunity/inflammation upregulating IL-12 IFN-γ pathway were studied. As an ex vivo model of endotoxemia, lipopolysaccharide (LPS) stimulated whole blood from 25 critically ill patients and 12 healthy individuals was incubated with either recombinant human (rh) IL-12 or rhIFN-γ, respectively. IFN-γ dose-dependently (P < .05) increased the release of IL-12 p40 and p70 into LPS-stimulated whole blood from healthy humans without effect in whole blood from critically ill patients. RhIL-12 p70 enhanced (P < .05) the secretion of IFN-γ in controls, while it was ineffective in LPS-stimulated whole blood from critically ill patients. The observed inhibition of the IL-12 IFN-γ pathway is not specific to LPS, since Staphylococcus aureus Cowan strain I (SAC)-stimulated whole blood from critically ill patients showed similar suppression. The secretion of IL-12 and IFN-γ was less reduced in critically ill patients when using isolated cultures of adherent cells or lymphocytes. Although preculture of whole blood from healthy humans with IL-10, but not with IL-4, mimicked suppression of the IL-12 IFN-γ pathway similar to that observed during critical illness, the release of antiinflammatory reacting cytokines (IL-4, IL-10, transforming growth factor [TGF]-β1 ) was decreased into LPS-stimulated whole blood from critically ill patients. These results indicate at least two mechanisms responsible for dramatic disturbances of the IL-12 IFN-γ pathway during critical illness: (1) deactivation of IL-12 and IFN-γ producing leukocytes in vivo early after the primary insult, and (2) presence of serum suppressive factors different from IL-4, IL-10, or TGF-β1 . Because IL-12 and IFN-γ upregulate essential immune functions, the marked inhibition of IL-12 and IFN-γ release may be pivotal for high susceptibility of critically ill patients to infection.


2014 ◽  
Vol 10 (4) ◽  
pp. 164-166
Author(s):  
Linda Degl’Innocenti ◽  
Flaviano Di Paola ◽  
Rizzo Marianna ◽  
Gerardino Amato

Critical Care ◽  
2009 ◽  
Vol 13 (Suppl 1) ◽  
pp. P381 ◽  
Author(s):  
H Murayama ◽  
Y Kakihana ◽  
T Oryoji ◽  
N Kiyonaga ◽  
S Tashiro ◽  
...  

Critical Care ◽  
2011 ◽  
Vol 15 (S3) ◽  
Author(s):  
N Matsumoto ◽  
G Takahashi ◽  
M Kojika ◽  
Y Ishibe ◽  
S Tatsuyori ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document